Japanese Retail Distributors Stock News

TSE:9435
TSE:9435Industrials

Hikari Tsushin (TSE:9435) Margin Strength And EPS Volatility Test Bullish Narratives

Hikari Tsushin (TSE:9435) has just posted its Q3 2026 update, with recent quarterly revenue running at about ¥194.5 billion in Q2 2026 and basic EPS of ¥960.21, against a backdrop where trailing 12 month EPS sat at ¥3,182.21 on revenue of roughly ¥722.5 billion. Over the past reported quarters, the company has seen revenue move from ¥173.0 billion in Q3 2025 to ¥187.7 billion in Q4 2025 and then to ¥194.5 billion in Q2 2026, while quarterly EPS shifted from ¥1,244.00 in Q3 2025 to ¥336.01 in...
TSE:7701
TSE:7701Electronic

The Bull Case For Shimadzu (TSE:7701) Could Change Following Its Currency-Fueled Reinvestment Pivot Into M&A

In February 2026, Shimadzu Corporation revised its full-year guidance, lifting expected net sales to ¥555,000 million while keeping operating profit and profit attributable to owners of parent unchanged, and simultaneously reported nine-month results showing higher sales and net income than a year earlier. An interesting angle is that Shimadzu attributes the stronger sales outlook mainly to yen depreciation, yet is choosing to reinvest the incremental benefit into M&A, R&D, and other...
TSE:8018
TSE:8018Luxury

Global Dividend Stocks To Enhance Your Portfolio

As global markets experience volatility driven by mixed economic signals and sector rotations, investors are increasingly seeking stability through dividend stocks. In this dynamic environment, selecting dividend stocks with strong fundamentals and consistent payout histories can offer a reliable income stream while enhancing portfolio resilience.
TSE:6920
TSE:6920Semiconductor

How Investors Are Reacting To Lasertec (TSE:6920) Upgraded Guidance And Higher Dividend Payout

Lasertec Corporation reported half-year results to December 31, 2025, with sales of ¥128,258 million and net income of ¥45,745 million, alongside announcing a second-quarter dividend increase to ¥132.00 per share from ¥115.00 a year earlier, payable on March 12, 2026. The company also raised its full-year fiscal 2026 guidance, citing earlier customer acceptance of products and a revised yen/US$ exchange rate assumption of ¥145 per US$ compared with ¥135 previously. We will examine how...
TSE:4901
TSE:4901Tech

FUJIFILM Holdings (TSE:4901) Valuation After Earnings Growth Guidance Update And Affirmed Dividend

What the latest earnings, guidance and dividend signal for investors FUJIFILM Holdings (TSE:4901) has given investors a fresh information set, combining third quarter and nine month earnings, new full year guidance for fiscal 2026, and an affirmed year end dividend outlook. The company reported third quarter sales of ¥857,354 million and net income of ¥73,143 million, alongside nine month sales of ¥2,429,717 million and net income of ¥193,375 million, each higher than the comparable period a...
TSE:4503
TSE:4503Pharmaceuticals

Assessing Astellas Pharma (TSE:4503) Valuation After Myrbetriq Patent Settlements With Lupin And Zydus

Why the Myrbetriq legal settlement matters for Astellas shareholders Astellas Pharma (TSE:4503) has just closed its U.S. patent disputes over overactive bladder drug Myrbetriq, securing settlement and upfront licensing payments from Lupin and Zydus, as well as ongoing per unit fees. For you as an investor, this combination of cash inflows and reduced legal uncertainty can influence how you view the earnings profile tied to Myrbetriq and its generic competition in the U.S. market. See our...
TSE:8136
TSE:8136Specialty Retail

Sanrio Company (TSE:8136) Valuation After Upgraded Earnings And Dividend Guidance

Sanrio Company (TSE:8136) has put investors on alert after a February 12 board meeting combined three shareholder focused moves: an upcoming stock split, higher full year earnings guidance, and an increased dividend forecast. See our latest analysis for Sanrio Company. Despite Sanrio’s stronger guidance and dividend outlook, the share price is currently ¥4,764, with a 3 month share price return of an 18% decline and a 1 year total shareholder return of a 22% decline, while the 5 year total...
TSE:4204
TSE:4204Industrials

Is Sekisui Chemical’s Completed ¥26.4b Buyback Altering The Investment Case For Sekisui Chemical (TSE:4204)?

Sekisui Chemical has now completed its previously announced share repurchase plan, buying back 10,000,000 shares (2.43% of shares) for ¥26,420.48 million by February 9, 2026. This completed buyback reduces the share count and may enhance per-share metrics, underlining management’s willingness to return capital to investors. Next, we’ll examine how the completion of this sizeable buyback program may influence Sekisui Chemical’s existing investment narrative. We've uncovered the 14 dividend...
TSE:4502
TSE:4502Pharmaceuticals

Takeda Pharmaceutical’s Valuation After FDA Priority Review And New AI Drug Discovery Collaboration

Takeda Pharmaceutical (TSE:4502) just cleared two meaningful milestones, with the U.S. FDA granting Priority Review for its narcolepsy type 1 candidate oveporexton and a new AI-focused drug discovery collaboration with Iambic. See our latest analysis for Takeda Pharmaceutical. The recent regulatory progress for oveporexton and the AI drug discovery partnership with Iambic come as Takeda’s shares trade at ¥5,609, with a 30-day share price return of 11.73%, a 90-day share price return of...
TSE:9434
TSE:9434Wireless Telecom

SoftBank’s Earnings per Share Gains Might Change The Case For Investing In SoftBank (TSE:9434)

SoftBank Corp. has reported past earnings for the nine months ended December 31, 2025, with sales of ¥5.20 trillion and net income of ¥485.52 billion, both higher than the previous year. The improvement in basic and diluted earnings per share from continuing operations suggests greater profit generation per share, which may influence how investors assess SoftBank’s earnings power. We’ll now examine how this growth in sales and net income shapes SoftBank’s broader investment narrative and...